Elan Touting Myobloc Manufacturing Process, Use In Botox Non-Responders
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The manufacturing process for Myobloc (botulinum toxin type B) may produce a product with greater biological activity than Allergan’s competing agent Botox (botulinum toxin type A), Elan suggested in a teleconference following approval of its cervical dystonia (CD) product.